Skip to Content
U.S. National Institutes of Health
Last Updated: 05/26/10

Spotlight On…

The Investigational Drug Steering Committee
In June 2005, the Clinical Trials Working Group, a broadly constituted panel with experts from academic research institutions, community oncology practices, the pharmaceutical and biotechnology industries, cancer patient advocacy groups, and government agencies recommended a series of initiatives to strengthen NCI’s clinical trials enterprise for the 21st century. More…

The NCI Experimental Therapeutics Program (NExT)
DCTD and the Center for Cancer Research (CCR) are working in close collaboration to reinvigorate cancer drug development at NCI. Through a joint early therapeutics development program, extramural and intramural teams have prioritized a pipeline of NCI-driven targeted therapeutics for development. This program, called the NCI Experimental Therapeutics (NExT) program, combines the strengths of DCTDs extensive expertise in anticancer drug development with CCRs dynamic in-house research and its location within state-of-the-art facilities at the NIH Clinical Center. More…

Operational Efficiency Working Group (OEWG)
CTEP is working with investigators to implement the recommendations of the OEWG presented by Dr. James Doroshow, Director of the NCI Division of Cancer Treatment and Diagnosis, to the NCI Clinical Trials and Translational Research Advisory Committee. The goal of the OEWG recommendations is to shorten the timeline necessary for trial activation. More…